Breaking News
0

Astellas Pharma Inc (ALPMY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.42 +0.05    +0.31%
15:47:00 - Closed. Currency in USD ( Disclaimer )
After Hours
16.42
0.00
0.00%
15:53:15 - Delayed Data
Type: Equity
Market: United States
ISIN: US04623U1025 
S/N: 04623U102
  • Volume: 206,228
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.32 - 16.44
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider
Astellas Pharma Inc 16.42 +0.05 +0.31%
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider

ALPMY Income Statement

 
Featured here, the Income Statement (earnings report) for Astellas Pharma Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
Period Ending: 2019
30/09
2019
30/06
2019
31/03
2018
31/12
Total Revenue 316336 334134 301320 357932
Revenue 316336 334134 301320 357932
Other Revenue, Total - - - -
Cost of Revenue, Total 68360 70512 64339 84171
Gross Profit 247976 263622 236981 273761
Total Operating Expenses 231226 257048 266779 275403
Selling/General/Admin. Expenses, Total 108597 117470 134479 124254
Research & Development 51467 53507 58723 50393
Depreciation / Amortization 4022 7178 8725 8819
Interest Expense (Income) - Net Operating 677 728 524 501
Unusual Expense (Income) - - -2148 10320
Other Operating Expenses, Total -1897 7653 2137 -3055
Operating Income 85110 77086 34541 82529
Interest Income (Expense), Net Non-Operating -54 -559 1598 2002
Gain (Loss) on Sale of Assets - - - -
Other, Net - 1 - -1
Net Income Before Taxes 85056 76528 36139 84531
Provision for Income Taxes 15046 18010 5409 -3139
Net Income After Taxes 70010 58518 30730 87670
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 70010 58518 30730 87670
Total Extraordinary Items - - - -
Net Income 70010 58518 30730 87670
Total Adjustments to Net Income -1 - - -1
Income Available to Common Excluding Extraordinary Items 70009 58518 30730 87669
Dilution Adjustment - - - -
Diluted Net Income 70009 58518 30730 87669
Diluted Weighted Average Shares 1886.98 1887.43 1903.32 1922.73
Diluted EPS Excluding Extraordinary Items 37.1 31 16.15 45.6
DPS - Common Stock Primary Issue 20 - 19 -
Diluted Normalized EPS 37.1 31 15.19 49.08
* In Millions of JPY (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALPMY Comments

Write your thoughts about Astellas Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email